AAD Licensed Content

The presentation reviewed the rapidly expanding pipeline of hidradenitis suppurativa (HS) therapies, emphasizing phase 2 and phase 3 trials and the growing number of studies over the past several years. It…

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

Pipeline of Emerging Hidradenitis Suppurativa Therapies in Phase 2 and 3 Trials

Description

The presentation reviewed the rapidly expanding pipeline of hidradenitis suppurativa (HS) therapies, emphasizing phase 2 and phase 3 trials and the growing number of studies over the past several years. It highlighted JAK inhibitors such as povorcitinib, upadacitinib, and topical ruxolitinib, noting generally meaningful improvements in abscess/inflammatory nodule counts and HiSCR response rates, with ongoing pediatric and adult phase 3 programs. It also covered IL-17 targeting sonelokimab, which showed promising phase 2 and early phase 3 results with improvements in HiSCR, draining tunnels, and higher response thresholds, including adolescent studies and long-term extensions. Additional mechanisms discussed included IL-1 blockade with lutikizumab, which showed dose-dependent efficacy but also safety concerns; BTK inhibition with remibrutinib, which showed encouraging early efficacy in phase 2 and is now in phase 3; and IL-36 inhibition with spesolimab, which had mixed results and no clear phase 3 success. Finally, the talk briefly mentioned other emerging approaches such as IL-1 pathway modulators, anti-NET therapy, interferon blockade, and dual-target biologics, concluding that HS research is rapidly advancing and offers substantial hope for improved future treatments.

View more

Conclusions

  • The hidradenitis suppurativa therapeutic pipeline is expanding rapidly, with a sharp increase in clinical trials and a sense that the field is entering an especially active period.
  • Several JAK inhibitors, especially povorcitinib and upadacitinib, show meaningful improvements in HS lesion counts and HiSCR responses, supporting continued phase 3 development.
  • Topical ruxolitinib appears promising for mild-to-moderate HS, with high response rates in early studies and ongoing larger trials to confirm benefit.
  • Sonelokimab, an IL-17A/F-targeting nanobody, has shown encouraging efficacy in phase 2 and phase 3 studies, including improvements in HiSCR and draining tunnels.
  • Lutikizumab, an IL-1 alpha/beta inhibitor, demonstrated signal of efficacy after anti-TNF failure, with stronger results at some dosing schedules and acceptable early safety overall.
  • Remibrutinib, a selective BTK inhibitor, produced favorable phase 2 outcomes in HiSCR and draining tunnel reduction and is now being tested in larger phase 3 trials.
  • Spesolimab did not clearly meet its primary phase 3 endpoint for HS, suggesting IL-36 blockade may have limited overall efficacy in this disease despite some improvements in secondary outcomes like tunnels and pain.
  • Although many agents show benefit, the most consistent gains appear to be in inflammatory lesion counts, HiSCR thresholds, and draining tunnel improvement rather than complete remission.
  • Safety data across the pipeline are generally manageable so far, but ongoing trials are important to better define adverse events for long-term and broader use.
  • The growing number of ongoing studies and off-label options suggests that patients with HS may soon have more targeted and potentially more effective treatment choices than before.
  • Future progress will likely come from both additional pathway-specific drugs and dual-target therapies designed for refractory disease.
  • Kirby et al., JAAD, 2024.
  • Ackerman et al., JAAD, 2025.
  • Porter et al., JAAD, 2026.
  • Porter et al., JAAD, 2026.
  • MoonLake Immunotherapeutics news release, September 28, 2025.
  • MoonLake Immunotherapeutics news release, November 5, 2025.
  • Alavi et al., BJD, 2024.